43rd Annual Meeting 
of the European Society for 

Blood and Marrow Transplantation
26-29 March 2017 • Marseille, France
SIGN UP FOR UPDATES
REGISTER NOW
  • Home

  • Meeting Information

  • Abstracts

  • Program

  • Registration & Accommodation

  • Media

  • Support & Exhibition

  • More

    Copyright © 2016 EBMT2017.org. All Rights Reserved
    Meeting Organizers
    CME Congresses
    P: +972 3 555 0188
    F: +972 3 540 1566
    ebmt@cme-congresses.com
    Venue 
    Palais des Congrès - Marseille Chanot 
    Parc Chanot, Rond-Point du Prado, 13009 Marseille, France 
    www.marseille-chanot.com
    Contact Information
    Abstracts
    ebmt.abstracts@cme-congresses.com

    Registration & Accommodation 
    ebmt.reg@cme-congresses.com
    Membership
    membership@ebmt.org

    RMEI Medical Education, LLC and Postgraduate Institute for Medicine:

    Sunday, March 26th

    11:00-12:30 - Les Goudes 1

    Optimizing Outcomes in CMV and GVHD in Stem Cell Transplant Patients: A Focus on Leading Causes of Morbidity and Mortality

    Industry sponsored and supported symposia

    Jazz Pharmaceuticals:

    Sunday, March 26th
    15:00-16:30 - Endoume 1+2

    A Nurse's Role in the Management of Acute Transplant Complications

    ​

    Monday, March 27th
    12:45-14:15 - Hall 2

    The Changing Picture of Transplant Complications: Real-life Examples

     

    Tuesday, March 28th
    13:00-14:00 - Les Goudes 2

    A Pharmacy Perspective on the Importance and Value of Effective Management of VOD in Post-HSCT Patients

    Basilea:

    Sunday, March 26th
    15:00-16:30 - Auditorium

    Insights and opportunities in IMD and haematological malignancies

    ​

    Tuesday, March 28th
    16:30-17:30 - Les Goudes 2

    Emerging issues for pharmacists and new agents in the management of IMD in haematological malignancies

    Pfizer:

    Sunday, March 26th
    11:00-12:30 - Hall 1

    Advances in the management of aplastic anaemia: An interactive symposium

    ​

    Sunday, March 26th

    13:00-14:30 - Hall 1

    Targeted approaches to improve outcomes in AML

    ​

    Sunday, March 26th

    17:00-18:45 - Les Goudes 2

    Redefining the ALL landscape through innovation

    Takeda:

    Sunday, March 26th
    15:00-16:30 - Hall 1

    The pivotal role of proteasome inhibition in myeloma treatment

     

    Tuesday, March 28th
    12:45-14:15 - Hall 2

    Time for change: Improving outcomes in CD30-positive lymphomas

    Amgen:

    Sunday, March 26th

    13:00-14:30 - Les Goudes 1

    Stem cell transplantation in multiple myeloma – Strategies and potential

    ​

    Sunday, March 26th
    15:00-16:30 - Les Goudes 1

    Considering transplant and T-cell engaging therapy in ALL

    Celgene:

    Sunday, March 26th
    17:00-18:00 - Amphithéâtre Callelongue

    60 Minutes to Revisit Allo-Transplant in HR MDS and AML

     

    Sunday, March 26th
    18:00-19:00 - Amphithéâtre Callelongue

    CAR-T Cell therapy: Today and tomorrow

    ​

    Monday, March 27th
    16:30-18:00 - Hall 2

    How Can We Raise the Bar in the Management of Transplant-Eligible Multiple Myeloma Patients?

    Sanofi-Genzyme:

    Sunday, March 26th

    11:00-13:00 - Amphithéâtre Callelongue

    GVHD: What's new in 2017?

    ​

    Sunday, March 26th

    14:30-16:30 - Amphithéâtre Callelongue

    Update on mobilization issues

    Miltenyi Biotec:

    Sunday, March 26th
    13:00-15:00 - Les Goudes 2

    Cellular therapy: Recent advances and future perspectives

    Molmed:

    Sunday, March 26th
    11:00-12:30 - Hall 2

    1956 – 2016: a long journey from the first successful BMT to the first successful patient-specific cell therapy in HSCT, approved by EC
     

    Tuesday, March 28th

    12:45-14:15 - Hall 1

    Nurses role in cell therapy management

    Mallinckrodt Pharmaceuticals (Therakos (UK) Ltd.):

    Sunday, March 26th
    17:00-19:00 - Les Goudes 1

    ECP Immunomodulation: The importance of avoiding immune dysfunction and inducing tolerance for GvHD patients

    ​

    Monday, March 27th
    12:45-14:15 - Hall 1

    Therakos Integrated Photopheresis: Value for Nurses and Patients through Education

    IFM:

    Sunday, March 26th

    09:00-10:30 - Les Goudes 1

    Multiple Myeloma in 2017: The IFM perspective

    Janssen:

    Sunday, March 26th
    17:00-19:00 - Endoume 1+2+3

    Novel agents in hematological malignancies: joining forces with transplantation?

    Oxford Immunotec:

    Sunday, March 26th
    13:00-14:30 - Hall 2

    Insights on New Developments in CMV Immune Monitoring and Alternative Therapies for HSCT Recipients

    SFGM-TC:

    Sunday, March 26th

    09:00-10:30 - Les Goudes 2

    Allo-HCT and pulmonary complications

    Kiadis:

    Sunday, March 26th
    11:00-12:30 - Les Goudes 2

    Advances in haploidentical stem cell transplantation and post-transplant immunotherapy

    GSK:

    Sunday, March 26th
    15:00–16:30 - Hall 2

    Pioneering progress in ADA-SCID with gene therapy

    MSD:

    Sunday, March 26th
    09:00-10:30 - Auditorium

    CMV infection in your hematology patient – what's standard, what's new?

     

    Sunday, March 26th
    11:00-12:30 - Auditorium

    Fungal Infections in Transplant Recipients: Managing the Continuum of Risk

    ​

    Sunday, March 26th
    17:00-18:30 - Auditorium

    A Novel Approach to prevent Recurrent C difficile Infections (CDI) in High Risk Patients